SCHEMBL4038366

SCHEMBL4038366

CC(Nc1nc(-c2ccccc2)cs1)c1ccc(COc2ccc(CC(=O)O)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
APP P05067 1/20 0.53
PPARD Q03181 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
ACACB O00763 1/20 0.48
ELOVL1 Q9BW60 1/20 0.47
PHGDH O43175 1/20 0.46
ROCK2 O75116 4/20 0.45
ROCK1 Q13464 3/20 0.45
FFAR1 O14842 1/20 0.45
WNT3A P56704 1/20 0.45
HPGD P15428 1/20 0.45
RORC P51449 1/20 0.45
NPC1 O15118 1/20 0.45
PKM P14618 1/20 0.45
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4029424 0.93 APP (0.54) MAPTALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4034136 0.79 MAPT (0.60) MAPTALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4038203 0.76 MAPT (0.62) MAPTALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL11385164 0.76 MEN1 (0.70) MAPTALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4038361 0.75 KMT2A (0.53) MAPTMEN1KMT2AL3MBTL1APP
SCHEMBL4038358 0.74 PPARD (0.47) APPPPARDNR1H4FFAR1
SCHEMBL1746811 0.73 FFAR1 (0.59) MAPTALDH1A1MEN1KMT2AAPP
SCHEMBL13200859 0.73 ELOVL1 (0.67) MAPTALDH1A1MEN1KMT2AAPP
SCHEMBL5585565 0.71 CSNK2A1 (0.71) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL1745242 0.71 MAPT (0.52) MAPTALDH1A1MEN1KMT2AAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1357115-B1 ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2009-06-17 EP disclosed
US-7238716-B2 Alkanoic acid derivatives process for their production and use thereof TAKEDA PHARMACEUTICALS COMPANY LIMITED (JP) 2007-07-03 US disclosed
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-25 US disclosed
EP-1357115-A1 ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058965-A1 Alkanoic acid derivatives process for their production and use thereof GPR119, ACOX1, ALK MAPT 4719/4885ALDH1A1 176/4885MEN1 3721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.